Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 2Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

Vincristine 5Methotrexate 5Dexamethasone 5Cytarabine 5Cyclophosphamide 5Inotuzumab Ozogamicin 4blinatumomab 3Rituximab 3Prednisone 3Doxorubicin 3venetoclax 2prednylidene 2pegaspargase 2merphos 2deltacortene 2Mercaptopurine 2Asparaginase 2olverembatinib 1ofatumumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1azathiopurine 1auricularum 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Spinal Puncture 1Specimen Handling 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡